Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals – TheStreet.com
TheStreet.com |
Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals
TheStreet.com Incyte (INCY) is benefitting from the competition between Merck (MRK) and Bristol-Myers Squibb (BMY) for cancer immunotherapy supremacy. On Sunday, Bristol and Incyte announced plans to test a combination therapy consisting of the Big Pharma’s … Merck’s Keytruda cancer drug records sales surgeFinancial Times The cost of cancer: new drugs show success at a steep priceKFGO |
|
You are here
P&T Community “Sleeping Beauty and the RTS® approach are a powerful combination to improve the manufacturing process and instill control over CAR-modified T cells co-expressing cytokines such as membrane-bound IL-15. The collaboration with Intrexon and Merck … |
Slate Magazine |
What Exactly Is Synthetic Biology? It’s Complicated.
Slate Magazine Maybe! But in the short term, they’re doing it in the service of synthetic biology more generally. It’s a discipline that brings together the insights and methodologies of computer science; engineering; and, of course, biology. It encompasses genetic … |
Yahoo Finance |
Kite Pharma Completes Filing for CAR–T Therapy with FDA
Yahoo Finance We note that axicabtagene ciloleucel is Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for … Kite keeps pressure on Novartis with CAR–T filingpharmaphorum Kite Pharma (KITE) Gaining After Presenting At AACR This WeekendEconomic Calendar Kite Pharma Inc (KITE) Announces Submission of Biologics License Application to FDA for Axicabtagene CiloleucelSmarter Analyst Energy Index all 101 news articles » |
Nasdaq |
Kite Pharma Completes Filing for CAR–T Therapy with FDA
Nasdaq We note that axicabtagene ciloleucel is Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for … Kite keeps pressure on Novartis with CAR–T filingpharmaphorum Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR–T Trial of Axicabtagene Ciloleucel in …Yahoo Finance |
|
Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR–T Platform …
GlobeNewswire (press release) “Sleeping Beauty and the RTS® approach are a powerful combination to improve the manufacturing process and instill control over CAR-modified T cells co-expressing cytokines such as membrane-bound IL-15. The collaboration with Intrexon and Merck … |